Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in marketable securities at December 31, 2023, were $329.4 million as compared to $505.0 million at December 31, 2022. Nektar's cash and marketable securities are expected to support strategic development activities and oper ...

On today's call, we expect to make forward-looking statements regarding our business, including statements regarding the therapeutic potential of and future development plans for drug candidates and research programs. The timing of the initiation of clinical studies and the availability of clinical data for drug candidates, the timing and plans for future clinical data presentations, the formation, future development plans or success of our collaboration agreements, the expectations following our corporate ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...

Nektar Therapeutics (NASDAQ:NKTR) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and CEO Dr. Jonathan Zalevsky - Chief, Research and Development Dr. Mary Tagliaferri - Chief Medical Officer Jennifer Ruddock - Chief Business Officer Sandra Gardiner - Acting Chief Financial Officer Cheng Li - Oppenheimer & Co. Inc. Mara Goldstein - Mizuho Kambiz Yazdi - Jefferies Daina Graybosch - Leerink Partners Good day and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2021 Earnings Conference Call November 4, 2021 5:00 PM ET I would now like to hand the conference over to your speaker today, Jennifer Ruddock, Head of Corporate Affairs. Please go ahead. Thank you, Crystal, and good afternoon, everyone. Thank you all for joining us today. With us on the call are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Chief of Research and Development; and Dr. Dimitry Nuyten, our Chief Medical Of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ Form 10-K ___________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and Chief Executive Officer Brian Kotzin - Chief Medical Officer Jonathan Zalevsky - Chief Research and Development Officer Jillian Thomsen - Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Roger Song - Jefferies Group LLC Jessica Fye - JPMorgan Chase & Co. Greg Harrison ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2021 Earnings Conference Call February 28, 2022 5:00 PM ET Company Participants Jennifer Ruddock ??? Head-Corporate Affairs Howard Robin ??? President and Chief Executive Officer Dimitry Nuyten ??? Chief Medical Officer Jonathan Zalevsky ??? Chief-Research and Development Gil Labrucherie ??? Chief Operating Officer and Chief Financial Officer Conference Call Participants Peter Lawson ??? Barclays CJ Zopf ??? Goldman Sachs Jessica Fye ??? JPMorgan Greg Harrison ??? Bank o ...